Pharmagreen Biotech

Pharmagreen Biotech FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Pharmagreen Biotech (PHBI) as of Nov 4, 2026 is -5.74 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 2.80 % — a change of -305.01% (lower).

FCF Conversion

-5.74 %

YoY

-305.01%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Pharmagreen Biotech is 2025 -5.74 % . FCF Conversion Rate (FCF/EBITDA) of Pharmagreen Biotech was 2024 2.80 % . It decreases by -305.01% lower compared to the previous year.

The Pharmagreen Biotech FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
96.54 USD
Jan 1, 2019
57.72 USD
Jan 1, 2020
18.28 USD
Jan 1, 2021
3.72 USD
Jan 1, 2022
48.75 USD
Jan 1, 2023
12.98 USD
Jan 1, 2024
2.80 USD
Jan 1, 2025
-5.74 USD
The Pharmagreen Biotech FCF Conversion history
YEARFCF ConversionYoY
-5.74 %-305.01%
2.80 %-78.44%
12.98 %-73.38%
48.75 %+1,210.31%
3.72 %-79.64%
18.28 %-68.34%
57.72 %-40.21%
96.54 %-26.66%
131.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pharmagreen Biotech Stock analysis

What does Pharmagreen Biotech do? Pharmagreen Biotech Inc is a Canadian company specializing in the production of cannabis plants. The company was founded in 2009. Initially, the company focused primarily on research in the field of plant biotechnology. It worked on developing plants with higher cold resistance for cultivation in colder regions. Research in breeding plants with higher nutritional value was also part of their focus. In 2017, the company recognized the incredible potential of the cannabis industry and decided to apply its expertise in this field. Pharmagreen Biotech Inc began large-scale production of cannabis plants, working closely with other industry leaders to optimize production and create the best possible conditions. Pharmagreen Biotech Inc places great importance on sustainability and environmental awareness. All production methods are designed with ecological sustainability in mind. The plants are grown in environmentally-friendly greenhouses and all waste is recycled and reused. The business model of Pharmagreen Biotech Inc is tailored to the needs of its customers. The company produces cannabis plants for the medical and recreational sectors. It offers various types of plants to meet the needs of customers, including plants for home cultivation to cater to the growing market for self-grown cannabis plants. Products offered by Pharmagreen Biotech Inc also include seeds, fertilizers, and specialized cultivation kits tailored to the needs of cannabis plants. The company works closely with laboratories and research institutions to maximize and optimize the quality and potency of its products. The company recently developed a new technology called "Speed Breeding," which allows for the rapid breeding of cannabis plants. This enables Pharmagreen Biotech Inc to serve an even larger portion of the market and provide faster availability of products for customers. Pharmagreen Biotech Inc is divided into various divisions, including medical cannabis production, recreational cannabis, plant products, and seed production. Each division is led by a specialized team focused on the needs and requirements of customers in that area. Overall, Pharmagreen Biotech Inc is an innovative and sustainable company focused on the needs of its customers. Its wide range of products and ongoing research and development make it an important player in the rapidly growing cannabis industry. Pharmagreen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pharmagreen Biotech stock

FCF Conversion Rate (FCF/EBITDA) of Pharmagreen Biotech is -5.74 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Pharmagreen Biotech changed from 2.80 % to -5.74 %, representing a -305.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Pharmagreen Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Pharmagreen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Pharmagreen Biotech

All Key Metrics — Pharmagreen Biotech